RE: Breathalyser Tweet20 Aug 2020 14:33
£50m is not much these days. The psoriasis market alone is worth £20bn+ globally, and Labskin are the only company using AI identifying to treat this. This only one type of skin problem through only one of their companies, and the market is there for the taking in all areas
The CEO certainly has the right attitude and credentials, and certainly one to be on his side. Definitely different to other directors on AIM or LSE, in a very positive way, just hope he can back up what he says and ABC (always be closing). Most directors will do placings and fritter the cash away way on hookers ,coke, champagne and unknown expenses, but I think GB is different. SKIN now accounts for 60% of my portfolio and have a view to hold long term ( i own 1/500ths of the company ).